ArticleDiscover oncology2025
Untargeted metabolomics reveals gut microbiota metabolite alterations and their correlation with serum biomarkers in gastric cancer patients from high-altitude regions.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to characterize gut microbiota-derived faecal metabolites and evaluate their associations with serum biochemical indices and tumor markers in gastric cancer patients residing in high-altitude regions, using untargeted metabolomics.
methodsStool samples from 30 newly diagnosed gastric cancer patients and 30 healthy controls from Qinghai Province were analyzed using LC-MS-based untargeted metabolomics. Serum biomarkers-including proteins, lipids, and tumor markers-were concurrently measured. Multivariate analysis, fold-change filtering, and correlation analysis were used to identify differential metabolites and their associations with clinical phenotypes. False discovery rate (FDR) correction was applied to reduce false positives.
resultsA total of 281 faecal metabolites were identified, predominantly lipids (35.4%) and organic acids (29.1%). Significant metabolic alterations were observed in gastric cancer patients, with notable upregulation of glycylproline, glycine, and hydroxyisocaproic acid, and downregulation of cytidine, 5'-methylthioadenosine, and trehalose. Correlation analysis revealed hydroxyisocaproic acid and glycine were positively associated with serum albumin, while 5'-methylthioadenosine was negatively correlated with HDL, LDL, and alpha-fetoprotein. Annotation was supported by MS/MS spectral matching and database scoring. Limitations included a modest sample size, limited control for high-altitude confounders, and lack of targeted validation.
conclusionGastric cancer patients living at high altitudes exhibit distinct gut microbiota metabolic profiles compared to healthy individuals. Specific faecal metabolites show significant associations with key serum biomarkers, suggesting a microbiota-metabolism-serum axis potentially influenced by environmental and pathological factors. These findings may inform biomarker discovery and future mechanistic studies focused on high-altitude cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.